Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
Journal of Hematology & Oncology|January 7, 2017
Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphomaYu Huang, Bo Jia, Shiyu Jiang, et al.
Molecular Diagnosis & Therapy|November 19, 2022
Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor LymphomaHaizhu Chen, Yan Qin, Peng Liu, et al.
The Oncologist|April 7, 2019
Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell LymphomaYing Han, Jianliang Yang, Peng Liu, et al.
European Journal of Haematology|June 9, 2023
Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patientsYan Qin, Xiaohui He, Xinrui Chen, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2021
Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from ChinaHaizhu Chen, Yan Qin, Jianliang Yang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 31, 2015
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]Shaoxuan Hu, Xiaohui He, Mei Dong, et al.
Leukemia & Lymphoma|July 23, 2021
Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphomaYunxia Tao, Xiaohui He, Yan Qin, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 28, 2015
[Efficacy analysis of different follow-up methods in detecting first recurrence of lymphoma]Jianliang Yang, Yuankai Shi, Xiaohui He, et al.
Asia-Pacific Journal of Clinical Oncology|July 3, 2019
A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patientsShiyu Jiang, Yan Qin, Peng Liu, et al.
Annals of Hematology|July 27, 2020
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphomaHaizhu Chen, Yan Qin, Jianliang Yang, et al.
Pageof 10